Evidence map›Paper›PMID 35092372›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Curcumin Encapsulated into Biocompatible Co-Polymer PLGA Nanoparticle Enhanced Anti-Gastric Cancer and Anti-Helicobacter Pylori Effect.

Jawed Alam, Fahima Dilnawaz, Sanjeeb Kumar Sahoo, Durg Vijai Singh, Asish Kumar Mukhopadhyay, Tahziba Hussain, Sanghamitra Pati

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Advances in nanomedicine and delivery systems for gastric cancer research.Frontiers in bioengineering and biotechnology · 2025
    Review
  14. Review
  15. Review
  16. Novel Drug Delivery Systems for CombatingArchives of Razi Institute · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jawed AlamDepartment of Immunology, ICMR-Regional Medical Research Centre, Bhubaneswar, India.ORCID 0000-0003-1176-0876
Fahima DilnawazDepartment of Cancer Biology, Institute of Life Science, Bhubaneswar, India.
Sanjeeb Kumar SahooDepartment of Cancer Biology, Institute of Life Science, Bhubaneswar, India.
Durg Vijai SinghDepartment of Infectious Diseases, Institute of Life Sciences, Bhubaneswar, India.
Asish Kumar MukhopadhyayDepartment of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, India.
Tahziba HussainDepartment of Immunology, ICMR-Regional Medical Research Centre, Bhubaneswar, India.
Sanghamitra PatiDepartment of Immunology, ICMR-Regional Medical Research Centre, Bhubaneswar, India.
National Institute of Cholera and Enteric Diseases · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current disadvantages (high cost, toxicity, resistance) of chemotherapy for gastric cancer opted people for alternative therapy from natural source. Curcumin (natural product) possess multiple biological activities but low bio-availability limits their uses as therapeutic. The Nano-formulation of curcumin increased the bioavailability and productivity of anti-cancer and anti-bacterial properties. The present study was initiated to determine the anti-cancer and anti-bacterial effect of Nano curcumin against gastric cancer and H. pylori.

methodsCurcumin loaded PLGA nanoparticles (CUR-NPs) was prepared by single emulsion solvent evaporation method. The MIC were determined using agar dilution method to find the anti-H. Pylori activity of Nano curcumin. The cytotoxicity of Nano curcumin was evaluated by MTT assay and the apoptotic effect (cell cycle arrest and morphology change) was shown by PI staining and microscopy.

resultsThe MIC of nanocurcumin and curcumin for all four H. pylori strains were 8 µg/ml and 16 µg/ml respectively. The inhibition rate of gastric cancer cells after treatment with curcumin was increased from 6% to 67% for 24h, from 8% to 75% for 48h, from 10% to 83% for 72h. In case of nanocurcumin, the inhibition rate increased from 7% to 69% for 24h, 11% to 87% for 48h and 16% to 97% for 72h. The IC50 of curcumin and Nano-curcumin were 24.20 µM and 18.78 µM respectively for 72 h. The population of cells in sub-G0 population increased from 4.1% in the control group to 24.5% and 57.8% when treated with curcumin and nanocurcumin respectively. After 72h of treatment with nanocurcumin, the apoptotic cells population increased as compared to native curcumin treated cells.

conclusionThe Nano curcumin might be used as a potential therapeutics against gastric cancer and H. Pylori. There is need of further in vivo study in order to validate CUR-NPs activity.

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsBiological AvailabilityCurcuminDrug Delivery SystemsHelicobacter pyloriHumansMicrobial Sensitivity TestsNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerStomach NeoplasmsAnti-Bacterial AgentsAntineoplastic AgentsCurcuminPolylactic Acid-Polyglycolic Acid CopolymerCytotoxicityGastric cancerH. pyloriIC50Nano curcumin

Identifiers

PMID35092372
PMCPMC9258655
OpenAlexW4210660390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.